Brief: Oramed Pharmaceuticals Inc - On Sept 1, 2022, Co And Its Subsidiary, Entered Into A Non-Binding Memorandum Of Agreement With Medicox Co. Ltd.
08/09/2022 22:13
Sept 8 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED PHARMACEUTICALS INC - ON SEPT 1, 2022, CO AND ITS
SUBSIDIARY, ENTERED INTO A NON-BINDING MEMORANDUM OF AGREEMENT
WITH MEDICOX CO., LTD.
* ORAMED PHARMACEUTICALS- MOA SET OUT BASIC COMMERCIAL
UNDERSTANDINGS BETWEEN PARTIES THAT WOULD FORM BASIS OF
DEFINITIVE DISTRIBUTION LICENSE AGREEMENT
* ORAMED - AGREEMENT WOULD GRANT MEDICOX EXCLUSIVE RIGHT &
LICENSE
TO APPLY FOR APPROVAL & DISTRIBUTE CO’S ORMD-0801, IN SOUTH
KOREA FOR 10 YEARS
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results